bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.080
+0.290 (7.65%)
At close: Mar 28, 2025, 4:00 PM
4.450
+0.370 (9.07%)
After-hours: Mar 28, 2025, 7:59 PM EDT
bluebird bio Revenue
In the year 2024, bluebird bio had annual revenue of $83.81M with 184.12% growth. bluebird bio had revenue of $38.52M in the quarter ending December 31, 2024, with 391.72% growth.
Revenue (ttm)
$83.81M
Revenue Growth
+184.12%
P/S Ratio
0.47
Revenue / Employee
$223,485
Employees
375
Market Cap
39.94M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLUE News
- 15 days ago - BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE - Business Wire
- 5 weeks ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. - PRNewsWire
- 5 weeks ago - Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC
- 5 weeks ago - bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs - Accesswire
- 5 weeks ago - Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch - Reuters
- 5 weeks ago - bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - Business Wire
- 5 weeks ago - High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models - CNBC
- 3 months ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire